Pharmicell Co Ltd
Company Profile
Business description
Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.
Contact
12F Chungho B/D
3-2 Nonhyun-dong Gangnam-gu
Seoul135-010
KORT: +82 234960114
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
161
Stocks News & Analysis
stocks
Investors overlooking ASX share’s potential
stocks
Cerebras sees blockbuster demand, setting stage for US AI IPO frenzy
stocks
What did Morningstar subscribers buy and sell in April?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,870.60 | 46.70 | -0.52% |
| CAC 40 | 7,952.55 | 129.72 | -1.61% |
| DAX 40 | 23,950.57 | 505.69 | -2.07% |
| Dow JONES (US) | 49,526.17 | 537.29 | -1.07% |
| FTSE 100 | 10,195.37 | 177.56 | -1.71% |
| HKSE | 25,962.73 | 426.31 | -1.62% |
| NASDAQ | 26,225.14 | 410.08 | -1.54% |
| Nikkei 225 | 61,409.29 | 1,244.76 | -1.99% |
| NZX 50 Index | 12,965.01 | 60.06 | -0.46% |
| S&P 500 | 7,408.50 | 92.74 | -1.24% |
| S&P/ASX 200 | 8,630.80 | 42.70 | -0.49% |
| SSE Composite Index | 4,135.39 | 42.53 | -1.02% |